Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr342.00 DKK
Change Today +3.00 / 0.88%
Volume 110.0K
BAVA On Other Exchanges
Symbol
Exchange
OTC US
OTC US
Frankfurt
As of 11:06 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

bavarian nordic a/s (BAVA) Snapshot

Open
kr342.00
Previous Close
kr339.00
Day High
kr344.00
Day Low
kr336.50
52 Week High
04/10/15 - kr393.00
52 Week Low
04/28/14 - kr100.00
Market Cap
9.5B
Average Volume 10 Days
275.1K
EPS TTM
kr0.96
Shares Outstanding
27.7M
EX-Date
--
P/E TM
356.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for BAVARIAN NORDIC A/S (BAVA)

Related News

No related news articles were found.

bavarian nordic a/s (BAVA) Related Businessweek News

No Related Businessweek News Found

bavarian nordic a/s (BAVA) Details

Bavarian Nordic A/S, a biotechnology company, researches, develops, and manufactures novel cancer immunotherapies and vaccines for infectious diseases. The company markets IMVANEX, a non-replicating smallpox vaccine in Europe, as well as markets under the IMVAMUNE name in Canada. It is developing PROSTVAC, a targeted immunotherapy candidate for the treatment of metastatic castration-resistant prostate cancer, which is in Phase III clinical trials in collaboration with the National Cancer Institute; and CV-301, an active cancer immunotherapy product candidate, which is in Phase II clinical trials to treat colon, breast, and other cancers. The company is also involved in the development of IMVAMUNE, a non-replicating vaccine for the treatment of smallpox that is in Phase III clinical trials in the United States; and IMVAMUNE freeze-dried to treat smallpox in the liquid frozen form, which is in Phase II clinical trials. In addition, it is developing various products to treat infectious diseases that are in preclinical stage, including MVA-BN Anthrax for the treatment of anthrax in humans and animals; MVA-BN Filo vaccine for ebola and marburg; MVA-BN vaccine for selected biological threats, such as foot-and-mouth disease virus and burkholderia; and MVA-BN respiratory syncytial virus vaccine. Further, the company is involved in the development of MVA-BN Brachyury, a novel, active immunotherapy designed to induce a robust T cell immune response against Brachyury, which is in Phase I trial. Bavarian Nordic A/S was founded in 1994 and is headquartered in Kvistgaard, Denmark.

422 Employees
Last Reported Date: 03/11/15
Founded in 1994

bavarian nordic a/s (BAVA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

bavarian nordic a/s (BAVA) Key Developments

Bavarian Nordic A/S Proposes Amendments to the Articles of Association

Bavarian Nordic A/S announced that AGM will be heldon April 23, 2015, to propose the amend Article 6 of the Articles of Association.

Bavarian Nordic A/S Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 05:00 PM

Bavarian Nordic A/S Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 05:00 PM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Paul Chaplin, Chief Executive Officer and President.

Bavarian Nordic A/S Announces Consolidated Earnings Results for the Year Ended December 31, 2014; Provides Earnings Guidance for the Fiscal Year 2015

Bavarian Nordic A/S announced consolidated earnings results for the year ended December 31, 2014. For the year, the company announced revenue of DKK 1,216.8 million compared to DKK 1,212.5 million for the same period a year ago. Income before interest and tax was DKK 16.7 million compared to DKK 33.4 million for the same period a year ago. Income before company tax was DKK 64.4 million compared to DKK 6.2 million for the same period a year ago. Net profit for the year was DKK 25.9 million or DKK 1.0 per basic share compared to net loss of DKK 46.7 million or DKK 1.8 per basic share for the same period a year ago. Cash flow from operating activities was DKK 38.7 million compared to DKK 147.1 million for the same period a year ago. Investments in intangible assets was DKK 53.6 million compared to DKK 111.0 million for the same period a year ago. Investments in property, plant and equipment was DKK 52.4 million compared to DKK 44.4 million for the same period a year ago. Net asset value was DKK 45.2 per share compared to DKK 37.4 per share a year ago. For 2015, the company expects revenue at the level of DKK 1,000 million and a break even result before interest and tax (EBIT).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAVA:DC kr342.00 DKK +3.00

BAVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bioporto A/S kr1.76 DKK +0.01
Chimerix Inc $39.48 USD -0.53
Emergent Biosolutions Inc $30.61 USD -0.22
GeoVax Labs Inc $0.18 USD +0.002
Valneva SE €4.00 EUR -0.04
View Industry Companies
 

Industry Analysis

BAVA

Industry Average

Valuation BAVA Industry Range
Price/Earnings 100.0x
Price/Sales 6.7x
Price/Book 6.7x
Price/Cash Flow 323.4x
TEV/Sales 6.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAVARIAN NORDIC A/S, please visit www.bavarian-nordic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.